LLY Jan 2025 250.000 call
| Previous close | 513.00 |
| Open | 520.63 |
| Bid | 554.75 |
| Ask | 563.80 |
| Strike | 250.00 |
| Expiry date | 2025-01-17 |
| Day's range | 513.00 - 520.63 |
| Contract range | N/A |
| Volume | |
| Open interest | 66 |
ZacksPlay These New ETFs to Tap Lucrative Weight Loss Drug Market
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
Investor's Business DailyDow Jones Futures Fall As Target Tumbles; Nvidia Looms Over Stock Market
The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?
BloombergWeight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo
(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But to reach the next level the biopharmaceutical developer likely needs a partner — or a buyer.Most Read from BloombergThese Flight Routes Suffer the World’s Worst TurbulenceOne Dead After Singapore Air Flight Hit By Severe Turbulence‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes Turbulence TerrorBarclays Managers Warn Some Staff to Prepare fo
